Colorectal Cancer

• Researchers at UCL and UCLH conducted a trial where patients with stage 2 or 3 colorectal cancer received just nine weeks of pembrolizumab immunotherapy before surgery, challenging the standard approach of surgery followed by months of chemotherapy. • Early results showed 59% of patients had no detectable cancer after completing immunotherapy and undergoing surgery, and after 33 months of follow-up, none of the patients have experienced a relapse. • This outcome represents a significant shift in colorectal cancer treatment protocols, suggesting that short bursts of targeted immunotherapy prior to surgery may deliver more durable results than conventional post-operative chemotherapy regimens.

• An NIH-funded mouse study shows chronic colitis induces long-lasting epigenetic changes in gut stem cells, boosting AP-1 transcription factor activity and tumor growth potential. • Researchers analyzed over 52,000 cells, finding damage memories persist more than 100 days after inflammation ends, heritable across new cells. • The findings from Broad Institute scientists explain how sustained inflammation elevates colorectal cancer risk through dynamic epigenome alterations.

March is Colorectal Cancer Awareness Month, with the CDC identifying colorectal cancer as the third most common cancer for both men and women in the United States. Cleveland Clinic registered dietitian Julia Zumpano emphasized that a healthy, diverse microbiome reduces inflammation, which is linked to increased colorectal cancer risk, and recommended dietary changes including high-fiber foods like whole grains, fruits, vegetables, and legumes alongside fermented and probiotic foods such as yogurt and kimchi. In addition to dietary modifications, regular physical activity has been shown to reduce colorectal cancer risk, though individuals experiencing persistent gastrointestinal symptoms should seek medical attention. The preventive approach focuses on gradual lifestyle transitions rather than overwhelming dietary overhauls.